Insider: KAPLAN GILLA Director - Tyra Biosciences, Inc.
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 28,231 | 0 | 28,231 |
| Value | $1,080,682.68 | $0.00 | $1,080,682.68 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 03/25/2026 | DDS | 14,295 | Direct | COM | $36.97 | $528,506.16 | 28,231 |
| 06/18/2025 | DDS | 9,568 | Direct | COM | $9.78 | $93,596.09 | 28,231 |
| 06/17/2025 | DDS | 10 | Direct | COM | $10.35 | $103.50 | 37,799 |
| 06/16/2025 | DDS | 6,814 | Direct | COM | $10.38 | $70,725.91 | 37,809 |
| 06/13/2025 | DDS | 15,000 | Direct | COM | $10.31 | $154,582.50 | 44,623 |
| 06/12/2025 | DDS | 30,000 | Direct | COM | $10.31 | $309,255.00 | 59,623 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2026 Zacks Investment Research